Investors Governance News SEC Filings Stock Resources News Investor Alerts All Years 2021 2020 2019 2018 2017 Go Advanced Search Nov 30, 2021 Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive... Nov 10, 2021 Recursion Provides Business Updates and Reports Third Quarter 2021 Financials - Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022 Recursion (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering,... Photos 1 Oct 7, 2021 Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,... Sep 29, 2021 Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering,... Aug 16, 2021 Recursion Appoints Jordan Christensen as Vice President of Engineering Christensen to lead Recursion's Toronto office, opening in 2021 Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Jordan Christensen as its Vice President of Engineering. In addition to leading all of... Show 5 per page «1234567»